113 related articles for article (PubMed ID: 11328779)
21. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae.
Madaras-Kelly KJ; Daniels C; Hegbloom M; Thompson M
J Antimicrob Chemother; 2002 Aug; 50(2):211-8. PubMed ID: 12161401
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.
Zhanel GG; Walkty A; Nichol K; Smith H; Noreddin A; Hoban DJ
Diagn Microbiol Infect Dis; 2003 Jan; 45(1):63-7. PubMed ID: 12573552
[TBL] [Abstract][Full Text] [Related]
23. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.
Millichap JJ; Pestova E; Siddiqui F; Noskin GA; Peterson LR
J Clin Microbiol; 2001 Jul; 39(7):2719-21. PubMed ID: 11427605
[TBL] [Abstract][Full Text] [Related]
26. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Pestova E; Millichap JJ; Noskin GA; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
[TBL] [Abstract][Full Text] [Related]
27. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
[TBL] [Abstract][Full Text] [Related]
28. New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.
Janoir C; Varon E; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 2001 Mar; 45(3):952-5. PubMed ID: 11181389
[TBL] [Abstract][Full Text] [Related]
29. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
30. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
32. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
33. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
34. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.
Zeller V; Janoir C; Kitzis MD; Gutmann L; Moreau NJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):1973-8. PubMed ID: 9303396
[TBL] [Abstract][Full Text] [Related]
35. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
Richardson DC; Bast D; McGeer A; Low DE
Antimicrob Agents Chemother; 2001 Jun; 45(6):1911-4. PubMed ID: 11353652
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Brenwald NP; Gill MJ; Wise R
Antimicrob Agents Chemother; 1998 Aug; 42(8):2032-5. PubMed ID: 9687402
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan.
Chen JY; Fung CP; Wang CC; Chu ML; Siu LK
Microb Drug Resist; 2003; 9(2):211-7. PubMed ID: 12820807
[TBL] [Abstract][Full Text] [Related]
39. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
40. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Frémaux A; Sissia G; Geslin P
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
